Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Q2 2019 Earnings Conference Call Transcript
Aug 08, 2019 • 08:30 am ET
Good morning. Welcome to Corbus Pharmaceuticals Quarterly Update Conference Call and Webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this conference is being recorded.
I would now like to turn the conference over to your host, Mr. Ted Jenkins, Senior Director, Investor Relations and Corporate Communications. Thank you, sir. You may begin.
Good morning, everyone, and thank you for joining us for the Corbus Pharmaceuticals second quarter 2019 update conference call and webcast.
At this time, I'd like to remind our listeners that remarks made during this call may state management's intentions, hopes, beliefs, expectations or projections of the future. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the Federal Securities Laws. These forward-looking statements are based on Corbus' current expectations and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from those contemplated by such forward-looking statements are discussed in the periodic reports Corbus files with the Securities and Exchange Commission. These documents are available in the Investors section of the company's website and on the Securities and Exchange Commission's website. We encourage you to review these documents carefully.
Joining me on the call today are Dr. Yuval Cohen, our Chief Executive Officer; Dr. Barbara White, our Chief Medical Officer; Sean Moran, our Chief Financial Officer; and Craig Millian, our Chief Commercial Officer.
With that, it is my pleasure to turn the call over to Yuval.
Thank you, Ted. Good morning, everyone, and thank you for joining us today. 2019 is so far shaping up to be a busy and eventful year for Corbus, in which we are making important progress towards our corporate, clinical and financial objectives.
I want to remind you all of what our vision is as a company. We believe that targeting the body's endocannabinoid system, also known as the ECS, holds significant potential to provide novel medicines for inflammatory, fibrotic and metabolic diseases. The ECS is a master regulator of these processes in the body through its main two GPCR receptors through ligands and associated enzymes. Since our founding in 2014, we have been focused on discovering, developing and now preparing to commercialize potential novel medications that modulate this powerful biological system. It is our belief that over the coming decade, novel medicines targeting the ECS will potentially reshape treatment options for many diseases. To provide further insight into this, on June 21st of this year, we held our Annual Research and Development Day in New York City. I think it's worthwhile summarizing the three topics we highlighted that morning. First, lenabasum. We continue to advance our four clinical programs. They all remain on schedule. Dr. Barbara White, our Chief Medical Officer, will provide the latest updates for each.
We look forward to the